NCT00058279View on ClinicalTrials.gov

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

February 28, 2003

Study Completion Date

August 31, 2006

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

BIOLOGICAL

ipilimumab

Trial Locations (1)

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00058279 - Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter